News

In the ongoing Phase II trial, the efficacy and safety of intravenous picoplatin (120mg/m squared) administered every 21 days in combination with full-dose docetaxel (75mg/m squared) with daily

The primary objectives of the Phase I open-label, dose-escalation study are to evaluate the safety and tolerability of HGS1029 as monotherapy in patients with advanced solid tumors, and

This three-arm, open-label, randomized, Phase III trial compared two different dose regimens of Torisel with investigators’ choice of therapy (IC) in patients with relapsed or refractory mantle cell

This effort includes an immediate workforce reduction of approximately 15% through attrition and termination of positions as well as a decrease in other expenses through improved operational efficiencies

The head-to-head study compared rivaroxaban with the US-approved dosing regimen for enoxaparin, the current standard of care, for the prevention of venous thromboembolism (VTE) following total knee replacement

In the pivotal study conducted in Quebec, Canada, patients with LPL-deficiency were first enrolled in an observation study and subsequently treated in a study in which there are

The Committee for Medicinal Products for Human Use (CHMP) recommends the use of Erbitux in the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, KRAS wild-type metastatic

According to the company, the DL900’s advanced technology platform has the capacity to support numerous original equipment manufacturers capabilities, including multi parameter recording and data storage of a

The Phase I trial enrolled 16 patients with advanced solid tumors who had received up to three prior regimens for metastatic disease. Patients were administered picoplatin followed by